(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 February 2012 (23.02.2012)

PCT

(10) International Publication Number
WO 2012/024242 A1

(51) International Patent Classification:
C07K 16/22 (2006.01) *A61P 21/00* (2006.01)
A61P 19/08 (2006.01)

(21) International Application Number:
PCT/US2011/047806

(22) International Filing Date:
15 August 2011 (15.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/374,095 16 August 2010 (16.08.2010) US

(71) Applicant *(for all designated States except US)*: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **HAN, Hq** [US/US]; 3353 Crossland Street, Thousand Oaks, California 91362 (US). **ARORA, Taruna** [US/US]; 5380 Via Pisa, Thousand Oaks, California 91320 (US). **CHEN, Qing** [US/US]; 4595 El Capitan Place, Camarillo, California 93012 (US). **LU, Hsieng Sen** [US/US]; 2758 Rainfield Avenue, Westlake Village, California 91362 (US). **ZHOU, Xiaolan** [US/US]; 3876 Rodene Street, Newbury Park, California 91320 (US).

(74) Agent: **PERKINS, Patricia Anne**; Law Department, 1201 Amgen Court West, Seattle, Washington 98119-3105 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2012/024242 A1

(54) **Title**: ANTIBODIES THAT BIND MYOSTATIN, COMPOSITIONS AND METHODS

(57) **Abstract**: There are disclosed selective myostatin antagonists (including antibodies), nucleic acids encoding them, and methods of making and using them. Neutralizing antibodies recognizing the conformational epitope near position 21 to 31 and position 50 to 60.